



*(Incorporated in the Cayman Islands with Limited Liability)*

Stock Code: 0575

18 December 2020

## ANNOUNCEMENT




*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

### OFFER TO GRANT SHARE OPTION

This announcement is made by Regent Pacific Group Limited (the “**Company**” and collectively with its subsidiaries, the “**Group**”) pursuant to Rule 17.06A of The Rules Governing the Listing of Securities (the “**HK Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**HK Stock Exchange**”).



The directors (the “**Directors**” or the “**Board**”) of the Company announces that on 17 December 2020, the Company offered to grant an option (the “**Option**”) to subscribe for 18,000,000 shares of US\$0.01 each in the Company (“**Share(s)**”) to an eligible participant, who is a director of certain subsidiaries of the Group, (the “**Grantee(s)**”) in accordance with the rules of the share option scheme of the Company adopted on 10 June 2016, named “Share Option Scheme (2016)”, subject to the acceptance by the Grantee (the “**Offer**”).



Details of the Offer/Option are set out below:

1. Date of the Offer (the “Offer Date”) : 17 December 2020.
2. Date of grant of the Option : The Offer will remain open for acceptance by the Grantee for a period of **28 days** (inclusive of and from the Offer Date), which is expiring on 13 January 2021, or the Offer will lapse. The Option **shall, following the acceptance, be deemed to have been granted and to have taken effect on the Offer Date.**
3. Exercise price of the Option : HK\$0.183, being the **higher** of:
  - (i) the nominal amount of a Share (US\$0.010 or HK\$0.078);
  - (ii) the closing price of the Shares as stated in the daily quotations sheet of the HK Stock Exchange on the Offer Date, which must be a business day; and
  - (iii) the average closing price of the Shares as stated in the daily quotations sheets of the HK Stock Exchange for the five business days immediately preceding the Offer Date.
4. Market price of Shares on the date of grant of the Option/Offer Date : HK\$0.179.
5. Exercise period of the Option : The Option, when granted, is exercisable within 10 years from the date of grant so long as the relevant option holder remains as an “Eligible Participant” under the Scheme. Within such exercise period, the option holder is entitled to exercise:
  - (i) as to one-third after the first anniversary date of the date of grant, provided that the Food and Drug Administration of the United States has approved the start of the Phase III clinical trial for Fortacin™;
  - (ii) as to one-third after an “out licencing deal” for the United States has been signed and announced; and
  - (iii) as to one-third on the successful completion of Study 008 (defined to mean it meets its primary and secondary end points) and the Food and Drug Administration of the United States has granted the new drug approval for Fortacin™.

Any entitlements unexercised in any prior period may be carried forward to the following periods but, in any event, must be exercised within 10 years from the date of grant of the relevant Option. All entitlements of the Option that remain unexercised at the tenth anniversary date of the date of grant will lapse.

Shareholders please note that:

- (1) No Offers have been made to any of the Directors, the Chief Executive Officer and the substantial shareholders of the Company or any of their respective associates;
- (2) No Offers have been made to any Grantees in respect of an Option to subscribe for the number of Shares which are in excess of the individual limit referred to in Rule 17.03(4) of the HK Listing Rules; and
- (3) No Offers have been made to any of the substantial shareholders or Independent Non-Executive Directors of the Company or any of their respective associates in respect of an Option to subscribe for the number of shares which are in excess of the limit referred to in Rule 17.04(1) of the HK Listing Rules.

Note: Unless otherwise specified herein, amounts denominated in US\$ have been translated, for the purpose of illustration only, into HK\$ using the exchange rate of US\$1.00 = HK\$7.80.

On Behalf of the Board of  
**Regent Pacific Group Limited**

Jamie Gibson  
*Executive Director*

**Directors of the Company:**

James Mellon (*Chairman*)\*  
Jamie Gibson (*Chief Executive Officer*)  
David Comba#  
Julie Oates#  
Mark Searle#  
Jayne Sutcliffe\*

\* *Non-Executive Directors*

# *Independent Non-Executive Directors*

Hong Kong, 18 December 2020